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Fidaxomicin (1, tiacumicin B, lipiarmycin A3) is a marketed antibiotic that is used in the treatment of C. difficile infections. Based on the analysis of a cryo-
EM structure of fidaxomicin binding to its target enzyme (RNA-polymerase), a cation-π interaction of the aromatic moiety with an arginine residue was 
identified. Therefore, the variation of the substituents and concurrently changing the electronic properties of the aryl moiety represents an interesting 
strategy in search for new fidaxomicin analogs. Herein, we report the first semisynthetic access to new fidaxomicin analogs with varying halogen substituents 
via a Pd-catalyzed hydrodechlorination reaction. Subsequent iodination gave access to the first iodo-fidaxomicin derivatives, which matched or improved 
antibacterial properties compared to fidaxomicin against Mycobacterium tuberculosis and Staphylococcus aureus ATCC 29213. 
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Introduction 
Fidaxomicin (1, tiacumicin B, lipiarmycin A3) constitutes a glycosylated 
macrocyclic lactone first discovered in 1972 in a culture of A. deccanensis[1–
3] and later re-isolated several times over the years.[4–11] This complex natural 
product has been introduced in the clinic and was reported to display 
superior properties compared to vancomycin and metronidazole.[12] 
Fidaxomicin shows a narrower spectrum of activity and it is particularly 
active against C. difficile, allowing the normal gut flora to recover.[13] 
Furthermore, fidaxomicin is poorly absorbed when orally administered, 
which reduces its side effects.[14] 
Over the last decades, the number of strains exhibiting reduced 
susceptibility and even resistance to antibiotics is increasing steadily in the 
clinic,[15]  which led various institutions such as governmental agencies and 
the World Health Organization to develop plans for action.[16][17] In the past, 
natural products were successfully used as lead structures for the 
development of new drugs with improved activities and properties.[18–20] 
Therefore, the synthesis of novel fidaxomicin derivatives can provide 
avenues to successfully combat antibiotic resistance[21] and consequently 
access to various fidaxomicin derivatives will be needed in future. 
Fidaxomicin is an RNA-Polymerase (RNAP) inhibitor with a unique mode of 
action.[22–28] The recent disclosure of cryo-EM structures[29,30]  
Figure 1. Section of the cryo-EM structure of fidaxomicin (1) binding to RNA polymerase 
(PDB-ID: 6FBV).[29] The cation-π interaction between β’R84 (magenta) and the 
dichloroorsellinate moiety of 1 (blue) is highlighted. 
 
of fidaxomicin binding to RNAP offers a tool for structural design of new 
derivatives. Notably, these cryo-EM structures reveal a cation-π interaction 
between the aromatic ring of fidaxomicin’s homodichloroorsellinic acid 
moiety and the RNAP residue β’R84 (Figure 1). Determination of 
fidaxomicin’s pKa-value (pKa=5.6)[31] confirms an acidic character of the 
phenol that will be mainly deprotonated in physiological environment and 
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Scheme 1. Comparison of previous work and this work. tiaM = halogenase, ∆tiaM = tiaM inactivated mutant. 
Variations on the substituents of this aromatic ring will therefore influence 
its electronic properties and thereby alters the binding properties to the 
enzyme. Besides total synthesis studies,[32–39] only a few examples of 
synthetic modifications on fidaxomicin are known to date.[29,40–43] 
Researchers from Abbott Laboratories investigated the replacement of 
chloride by implementation of bromide into the natural product, by 
supplying the fermentation broth of D. aurantiacum subsp. hamdenensis 
with bromide (Scheme 1).[44,45] Later, Zhang and coworkers performed gene-
knockout studies to elucidate the biosynthetic pathway.[46,47] According to 
their study, the halogenase TiaM is not only able to insert chloride to the 
homoorsellinic acid moiety, but also bromide can be introduced. However, 
the introduction of other halogen atoms was not achieved in this study.  
 
2 
In this context, we were interested in replacing the Cl-substituents from the 
natural product by semisynthetic approaches to study the influence of these 
substituents on the antibacterial properties of fidaxomicin.  
Results and Discussion 
More recent results of Zhang and coworkers also showed improved activity 
for dechlorinated fidaxomicin derivatives.[46] Attracted by these results, we 
investigated a method for the preparation of such derivatives by using a 
semisynthetic approach from the natural product. Nevertheless, the direct 
transformation of aryl chlorides to aryl iodides is considered rather difficult. 
Indeed, exchange of a chlorine to a heavier halogen atom lead to the 
formation of a less stable compound (bond dissociation energies: Ph-Cl (407 
kJ mol-1) vs. Ph-I (280 kJ mol-1)).[48] Therefore, usually Cu– and Ni–mediated 
Finkelstein-type reactions are performed under harsh conditions (>100 °C) 
even for comparatively simple substrates,[48,49] potentially limiting their 
synthetic application with sensitive functional groups and/or scaffolds. 
Nevertheless, we decided to experimentally evaluate some of these 
Finkelstein reactions and found that either no conversion or upon increasing 
the temperature to above 150 °C decomposition of 1 was observed, 
rendering this classical approach not suitable in our case. Introduction of 
electron-withdrawing substituents like acetyl-protection of the phenolic 
hydroxy groups was not successful neither. We therefore turned our 
attention to the use of milder two-step procedures involving Pd-catalyzed 
silylations or borylations followed by an iodination step to access the desired 
iodinated derivatives.[50,51] To our delight, Buchwald’s Pd-catalyzed silylation 
of aryl chlorides[51] led to formation of traces of dehalogenated fidaxomicins 
2, 3 and 4, which indicated that the oxidative addition step into the hindered 
and unreactive C-Cl bonds of the homoorsellinic acid moiety took place. 
Unfortunately, efforts to promote the reductive elimination using bulkier 
phosphine ligands such as tBu-Davephos did not lead to any improvement. 
Nevertheless, encouraged by this result, we thus decided to study the 
reactivity of B2pin2 towards this reaction and we were pleased to obtain 
complete conversion to a mixture of mono- and didechlorinated compounds 
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Scheme 2. Optimized conditions for the preparation of dechloro-fidaxomicin 
derivatives 2–4. 
 
Intrigued by the mechanism and the difference of reactivity between Me6Si2 
and B2pin2, we performed control experiments in order to clarify the role of 
each reagent in these reaction conditions. Treatment of fidaxomicin under 
these conditions without water, base or the diboron source, respectively, 
led to the formation of only traces of the desired product, indicating their 
pivotal role.  
Further mechanistic investigations using D2O led to deuterium incorporation 
as evidenced by UHLC-MS and NMR  measurements (40-70% D-
incorporation, see SI). Water as the potential H atom source was already 
reported in reductive Heck reactions and transfer hydrogenations.[52,53] We 
propose that due to steric hindrance of the fully substituted aromatic system, 
reductive elimination is disfavored allowing formation of a Pd-hydride 
species which then undergoes reductive elimination to form the product 
(Scheme 3).[54] Involvement of a cyclic boronate ester formed with the 
phenolic hydroxy group is also conceivable and the presence of many acidic, 
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Scheme 4. Iodination of dechlorinated fidaxomicins 2-4. 
 
3 
Having dechlorinated compounds 2-4 in hands, we further investigated the 
iodination via electrophilic aromatic substitution using periodic acid and 
iodine,[55,56] which delivered diiodinated fidaxomicin 5 as well as 
monoiodinated compounds 6 and 7 (Scheme 4a). Due to the difficult 
purification of the dechlorination step, this reaction was performed on a 
crude mixture resulting in higher overall yields. Interestingly, mono-
iodinated compound 8 was only formed when performing the reaction on 
purified didechlorinated fidaxomicin 2 (Scheme 4b). We assume that  
residual Pd- or B-impurities from the previous step might interfere with this 
reaction, leading to diiodofidaxomicin 5 when performing the reaction on 
the mixture. Additionally, chlorine to iodine exchange might also be possible 
under these conditions. In any case, from an analog generation perspective, 
these observations were useful in the context of this study. 
The biological activities were evaluated by determination of the minimum 
inhibitory concentration (MIC) against different strains, including S. aureus, 
M. tuberculosis as well as several isolates of C. difficile (Figure 2 and Table 
1). The dechlorinated as well as iodinated fidaxomicin analogs retain their 
excellent activity against C. difficile (Figure 2). Mono-dechlorinated 
compounds 3 and 4, as well as chloroiodofidaxomicin 6 and 7 display very 
similar activity compared to fidaxomicin (1) with only a slight decrease in 
activity. The same trend is evident against S. aureus and M. tuberculosis 
(Table 1).  
Interestingly, chloroiodofidaxomicin 7 displays improved activity against M. 
tuberculosis compared to fidaxomicin (1). Against S. aureus, several 
compounds display equal potency (e.g. 3 and 6) or improved antibiotic 
activity, such as 4 and 7.  
 
 
Table 1. Minimum inhibitory concentrations [µg/mL] of compounds 1-8 against M. 
tuberculosis and S. aureus 
Compound 
MIC [μg/mL] 
M. tuberculosisa S. aureus 
1 0.25 8-16 
2 0.25 − 
3 0.25 8 
4 0.5 4 
5 0.25−0.5 16 
6 0.25 8 
7 0.12 4-8 
8 0.25−0.5 16 
















































































C. difficile 8282 (rt 017)
C. difficile ATCC 700057
C. difficile BAA-1805
C. difficile BAA-1875
C. difficile ATCC 9689 (rt 001)
C. difficile 8260 (rt 017)
C. difficile ATCC 43255
C. difficile 5680 (rt 027)
C. difficile 8264 (rt 027)







Figure 2. Minimum inhibitory concentrations [µg/mL] of compounds 1-8 against C. difficile isolates. 
 
Conclusions 
In this study, we developed a semisynthetic method towards dechlorinated 
and iodinated fidaxomicin compounds and investigated their antibiotic 
activity against the Gram-positive bacterial strains S. aureus, M. tuberculosis 
and various isolates of C. difficile. These studies revealed that all derivatives 
maintain their excellent antibacterial properties, even though slightly 
decreased in comparison to the parent compound 1. Compared to already 
known strategies towards fidaxomicin analogs possessing substituents 
different from Cl at the aromatic moiety, this investigation represents the 
first semisynthetic approach towards these halogenated compounds and 
provides a basis for further modifications which are currently under 
investigation in our labs.  
 
Experimental Section 
4’’’,6’’’-Didechlorofidaxomicin (2), 6’’’-Dechlorofidaxomicin (3) and 
4’’’-Dechlorofidaxomicin (4) 
A microwave tube was charged with commercially available fidaxomicin (1, 
100 mg, 94.5 µmol, 1.0 eq.), Pd2dba3·CH3Cl (43.3 mg, 41.8 µmol, 44 mol%), 
CyJohnPhos (49.7 mg, 0.142 mmol, 1.5 eq.), KF (11.0 mg, 189 µmol, 2.0 eq.) 
and B2pin2 (72.0 mg, 0.284 mmol, 3.0 eq.) and the flask was evacuated and 
flushed with argon several times. The solids were dissolved in dry dioxane 
(2.0 mL, degassed by freeze-pump-thaw (3x)). Then, H2O (25 µL, 1.4 mmol, 
15 eq.) was added and the mixture was allowed to stir at 100 °C for 24 h. 
The reaction mixture was filtered over Celite and the solvent was 
evaporated. The crude mixture was pre-purified by silica-gel column 
chromatography (CH2Cl2 to MeOH/CH2Cl2 1:9) and the product containing 
fractions were further purified by preparative RP-HPLC (Gemini NX C18, 5 µ, 
110 Å, 250 mm × 21.2 mm; solvent A: H2O + 0.1% HCOOH, solvent B: MeCN 
+ 0.1% HCOOH; 20 mL/min; LC time program (min –% B): 0.0 – 50%, 15.0 – 
50%, 45.0 – 55%, 46.0 – 100%] to afford 2 (tR = 14.2 min, 10.2 mg, 10.3 µmol, 
11%), 3 (tR = 17.3 min, 8.7 mg, 8.5 µmol, 9%) and 4 (tR = 18.5 min, 4.0 mg, 
3.9 µmol, 4%) as colorless solids. 
2 0.5 0.5 0.5 0.5 0.5 2 2 
1 0.5 0.5 0.25 0.12 0.06 1 1 1 2 3 4 
5 6 8 7 
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2: Rf = 0.44 (MeOH/CH2Cl2 1:18); Specific Rotation [𝛼𝛼]𝐷𝐷25 °𝐶𝐶  = −5.75 (c = 0.49, 
MeOH); FT-IR ?̃?𝜈 (film) 3439, 2977, 2934, 2877, 1700, 1644, 1621, 1589, 1453, 
1385, 1371, 1320, 1256, 1197, 1162, 1070, 1029, 1008, 901, 853 cm−1; 1H 
NMR (500 MHz, acetone-d6) δ 7.23 (d, J = 11.4 Hz, 1H), 6.68 – 6.58 (m, 1H), 
6.31 (d, J = 2.5 Hz, 1H), 6.24 (d, J = 2.5 Hz, 1H), 5.96 (ddd, J = 14.7, 9.6, 4.6 
Hz, 1H), 5.83 (s, 1H), 5.63 (t, J = 7.0 Hz, 1H), 5.26 – 5.20 (m, 1H), 5.12 (t, J = 
9.7 Hz, 1H), 5.00 (d, J = 10.1 Hz, 1H), 4.78 (d, J = 1.2 Hz, 1H), 4.76 – 4.70 (m, 
1H), 4.68 (d, J = 0.8 Hz, 1H), 4.60 (d, J = 11.5 Hz, 1H), 4.41 (d, J = 11.4 Hz, 1H), 
4.30 – 4.24 (m, 1H), 4.09 – 3.94 (m, 4H), 3.84 – 3.78 (m, 2H), 3.73 (m, 3H), 
3.64 – 3.59 (m, 1H), 3.57 (m, 1H), 3.51 (s, 3H), 3.33 – 3.22 (m, 1H), 2.92 – 
2.83 (m, 2H), 2.81 – 2.62 (m, 3H), 2.56 (sept, J = 7.0 Hz, 1H), 2.52 – 2.40 (m, 
2H), 1.98 – 1.90 (m, 1H), 1.81 (d, J = 1.3 Hz, 3H), 1.73 (d, J = 1.3 Hz, 3H), 1.66 
(s, 3H), 1.31 – 1.24 (m, 1H), 1.27 (d, J = 6.2 Hz, 3H), 1.23 – 1.12 (m, 15H), 1.09 
(s, 3H), 0.83 (t, J = 7.4 Hz, 3H) ppm; 13C NMR (126 MHz, acetone-d6) δ 176.8, 
171.7, 167.8, 165.8, 163.4, 150.6, 145.4, 143.4, 136.9, 136.12, 136.09, 133.8, 
128.2, 126.3, 125.4, 124.0, 111.0, 105.3, 101.9, 101.8, 96.8, 93.3, 81.8, 78.2, 
76.7, 75.7, 73.8, 72.9, 72.8, 72.4, 70.8, 70.2, 67.7, 63.4, 61.7, 42.0, 37.3, 34.8, 
30.2, 28.7, 28.4, 26.5, 20.7, 19.4, 19.2, 18.6, 18.3, 17.5, 16.6, 15.2, 13.8, 11.2 
ppm; HRMS ESI(+) (MeOH) calculated for C52H76O18Na [M+Na]+: 1011.49239, 
found: 1011.49031. 
3: Rf = 0.15 (MeOH/CH2Cl2 1:18); Specific Rotation [𝛼𝛼]𝐷𝐷25 °𝐶𝐶  = −4.85 (c = 0.51, 
MeOH); FT-IR ?̃?𝜈 (film) 3440, 2977, 2934, 2876, 1700, 1645, 1605, 1417, 1372, 
1314, 1258, 1198, 1146, 1071, 1028, 901, 853, 802, 695, 638, 620, 578, 554, 
534, 511, 497, 477, 464, 453 cm−1; 1H NMR (500 MHz, acetone-d6) δ 7.23 (d, 
J = 11.4 Hz, 1H), 6.63 (dd, J = 15.0, 11.5 Hz, 1H), 6.51 (s, 1H), 5.96 (ddd, J = 
14.7, 9.5, 4.6 Hz, 1H), 5.83 (s, 1H), 5.63 (t, J = 8.3 Hz, 1H), 5.22 (dt, J = 10.5, 
1.3 Hz, 1H), 5.13 (t, J = 9.7 Hz, 1H), 5.00 (d, J = 10.1 Hz, 1H), 4.78 (s, 1H), 4.76 
– 4.70 (m, 1H), 4.69 (s, 1H), 4.60 (d, J = 11.54 Hz, 1H), 4.42 (d, J = 11.4 Hz, 
1H), 4.29 – 4.24 (m, 1H), 4.03 (quint, J = 6.3 Hz, 1H), 3.95 (d, J = 2.3 Hz, 1H), 
3.82 (dd, J = 9.8, 3.4 Hz, 1H), 3.76 – 3.71 (m, 2H), 3.65 – 3.60 (m, 1H), 3.58 
(d, J = 3.3 Hz, 1H), 3.52 (s, 3H), 2.94 – 2.78 (m, 2H), 2.77 – 2.60 (m, 3H), 2.56 
(sept, J = 6.9 Hz, 1H), 2.51 – 2.38 (m, 2H), 1.99 – 1.91 (m, 1H), 1.81 (s, 3H), 
1.73 (s, 3H), 1.66 (s, 3H), 1.30 (d, J = 6.1 Hz, 3H), 1.26 – 1.23 (m, 1H), 1.23 – 
1.12 (m, 15H), 1.09 (s, 3H), 0.83 (t, J = 7.4 Hz, 3H) ppm; 13C NMR (126 MHz, 
acetone-d6) δ 176.8, 171.5, 167.8, 160.8, 159.1, 148.0, 145.4, 143.4, 136.9, 
136.12, 136.09, 133.8, 128.2, 126.3, 125.3, 124.0, 110.8, 106.7, 106.2, 101.8, 
96.8, 93.3, 81.8, 78.2, 77.3, 75.7, 73.8, 72.86, 72.81, 72.3, 70.7, 70.2, 67.7, 
63.4, 61.7, 42.0, 37.3, 34.8, 29.8, 28.7, 28.4, 26.5, 20.7, 19.4, 19.2, 18.6, 18.3, 
17.5, 16.5, 15.2, 13.8, 11.2 ppm; HRMS ESI(+) (MeOH) calculated for 
C52H75ClO18Na [M+Na]+: 1045.45341, found: 1045.45320. 
4: Rf = 0.15 (MeOH/CH2Cl2 1:18); Specific Rotation [𝛼𝛼]𝐷𝐷25 °𝐶𝐶  = −7.77 (c = 0.95, 
MeOH); FT-IR ?̃?𝜈 (film) 3432, 2977, 2934, 2876, 1698, 1645, 1610, 1580, 1450, 
1384, 1370, 1318, 1243, 1199, 1155, 1069, 1028, 901, 848, 799 cm−1; 1H NMR 
(500 MHz, acetone-d6) δ 7.23 (d, J = 11.4 Hz, 1H), 6.63 (dd, J = 15.0, 11.5 Hz, 
1H), 6.48 (s, 1H), 5.96 (ddd, J = 14.6, 9.5, 4.6 Hz, 1H), 5.83 (s, 1H), 5.63 (t, J = 
8.3 Hz, 1H), 5.22 (dt, J = 10.5, 1.3 Hz, 1H), 5.09 (t, J = 9.7 Hz, 1H), 5.00 (d, J = 
10.1 Hz, 1H), 4.78 (d, J = 1.2 Hz, 1H), 4.76 – 4.70 (m, 1H), 4.67 (s, 1H), 4.60 
(d, J = 11.5 Hz, 1H), 4.42 (d, J = 11.5 Hz, 1H), 4.29 – 4.24 (m, 1H), 4.03 (quint, 
J = 6.2 Hz, 1H), 3.96 (d, J = 3.0 Hz, 1H), 3.82 (dd, J = 9.8, 3.4 Hz, 1H), 3.76 – 
3.71 (m, 2H), 3.65 – 3.60 (m, 1H), 3.58 (d, J = 3.3 Hz, 1H), 3.52 (s, 3H), 2.94 – 
2.78 (m, 2H), 2.77 – 2.60 (m, 3H), 2.56 (sept, J = 6.9 Hz, 1H), 2.51 – 2.38 (m, 
2H), 1.99 – 1.91 (m, 1H), 1.81 (s, 3H), 1.73 (s, 3H), 1.66 (s, 3H), 1.28 (d, J = 
6.2 Hz, 3H), 1.26 – 1.23 (m, 1H), 1.23 – 1.12 (m, 15H), 1.09 (s, 3H), 0.83 (t, J 
= 7.4 Hz, 3H) ppm; 13C NMR (126 MHz, acetone-d6) δ 176.8, 170.1, 167.8, 
160.9, 158.2, 145.4, 145.2, 143.5, 136.9, 136.10, 136.08, 133.8, 128.1, 126.3, 
125.3, 124.0, 114.1, 109.5, 102.8, 101.8, 96.8, 93.3, 81.7, 78.2, 77.0, 75.7, 
73.8, 72.9, 72.8, 72.4, 70.8, 70.2, 67.7, 63.4, 61.7, 42.0, 37.3, 34.8, 28.7, 28.3, 
26.5, 26.3, 20.7, 19.4, 19.2, 18.6, 18.2, 17.5, 15.2, 14.4, 13.8, 11.2 ppm; 
HRMS ESI(+) (MeOH) calculated for C52H75ClO18Na [M+Na]+: 1045.45341, 
found: 1045.45374. 
4’’’,6’’’-Diiodofidaxomicin (5), 6’’’-Iodofidaxomicin (6) and 4’’’-
Iodofidaxomicin (7) 
A mixture of 2, 3 and 4 (94.5 µmol, 1.0 eq.) was dissolved in EtOH (1.8 mL) 
and cooled to 0 °C. Then, I2 (24.0 mg, 94.5 µmol, 1.0 eq.) was added in one 
portion and a solution of H5IO6 (6.5 mg, 28 µmol, 0.3 eq.) in H2O (100 µL) was 
added dropwise. The reaction mixture was stirred at 0 °C for 1 h and was 
then allowed to slowly warm to room temperature within 2 h. Subsequently, 
it was diluted with EtOAc (10 mL) and then quenched with 10% aq. Na2S2O3 
(10 mL). The phases were separated, and the aqueous layer was extracted 
with EtOAc (3 x 10 mL). The combined organic layers were dried over MgSO4, 
filtered and the solvent was evaporated under reduced pressure. The crude 
mixture was purified by preparative RP-HPLC (Gemini NX C18, 5 µ, 110 Å, 
250 mm × 21.2 mm; solvent A: H2O + 0.1% HCOOH, solvent B: MeCN + 0.1% 
HCOOH; 20 mL/min; LC time program (min –% B): 0.0 – 50%, 15.0 – 50%, 
45.0 – 70%, 46.0 – 100%] to afford, after lyophilization, 5 (tR = 25.0 min, 9.5 
mg, 7.6 µmol, 9%), 6 (tR = 27.5 min, 13.6 mg, 11.8 µmol, 13%), and 7 
(tR = 32.0 min, 6.1 mg, 5.3 µmol, 5%) as colorless solids. 
5: Rf = 0.21 (MeOH/CH2Cl2 1:18); Specific Rotation [𝛼𝛼]𝐷𝐷24 °𝐶𝐶  = −1.96 (c = 0.26, 
MeOH); FT-IR ?̃?𝜈 (film) 3432, 2976, 2932, 2875, 1733, 1698, 1644, 1468, 1449, 
1384, 1370, 1308, 1244, 1198, 1149, 1069, 1026, 901, 799, 767 cm−1; 1H NMR 
(500 MHz, acetone-d6) δ 7.24 (d, J = 11.4 Hz, 1H), 6.68 – 6.58 (m, 1H), 5.96 
(ddd, J = 14.7, 9.6, 4.6 Hz, 1H), 5.83 (s, 1H), 5.63 (t, J = 8.4 Hz, 1H), 5.22 (d, J 
= 10.5 Hz, 1H), 5.10 (t, J = 9.7 Hz, 1H), 5.00 (d, J = 10.1 Hz, 1H), 4.78 (s, 1H), 
4.76 – 4.72 (m, 1H), 4.68 (s, 1H), 4.60 (d, J = 11.5 Hz, 1H), 4.43 (d, J = 11.5 Hz, 
1H), 4.30 – 4.24 (m, 1H), 4.08 – 3.99 (m, 1H), 3.95 (d, J = 3.5 Hz, 1H), 3.85 – 
3.78 (m, 1H), 3.76 – 3.69 (m, 2H), 3.65 – 3.59 (m, 2H), 3.52 (s, 3H), 3.13 – 
3.02 (m, 2H), 2.79 – 2.61 (m, 3H), 2.56 (sept, J = 7.1 Hz, 1H), 2.53 – 2.39 (m, 
2H), 1.96 – 1.90 (m, 1H), 1.81 (s, 3H), (m, 15H), 1.09 (s, 3H), 0.83 (t, J = 7.4 
Hz, 3H) ppm; 13C NMR (126 MHz, acetone-d6) δ 176.8, 169.1, 167.8, 160.6, 
160.0, 149.4, 145.5, 143.5, 136.9, 136.11, 136.09, 133.8, 128.1, 126.3, 125.2, 
123.9, 110.1, 101.7, 96.8, 93.3, 82.4, 81.6, 78.2, 77.6, 75.7, 73.8, 73.2, 72.9, 
72.8, 72.4, 70.6, 70.2, 67.7, 63.3, 61.7, 42.0, 37.3, 34.8, 34.3, 28.7, 28.4, 26.5, 
20.7, 19.4, 19.2, 18.6, 18.2, 17.5, 15.2, 14.7, 13.8, 11.2 ppm; HRMS ESI(+) 
(MeOH) calculated for C52H74I2O18Na [M+Na]+: 1263.28567, found: 
1263.28567. 
6: Rf = 0.23 (MeOH/CH2Cl2 1:18); Specific Rotation [𝛼𝛼]𝐷𝐷26 °𝐶𝐶  = −7.68 (c = 0.28, 
MeOH); FT-IR ?̃?𝜈 (film) 3435, 2977, 2934, 2876, 1732, 1697, 1644, 1453, 1407, 
1370, 1308, 1245, 1199, 1164, 1147, 1069, 1026, 901, 799 cm−1; 1H NMR 
(500 MHz, acetone-d6) δ 7.24 (d, J = 11.5 Hz, 1H), 6.70 – 6.57 (m, 1H), 5.96 
(ddd, J = 14.7, 9.6, 4.7 Hz, 1H), 5.83 (s, 1H), 5.68 – 5.58 (m, 1H), 5.22 (d, J = 
10.5 Hz, 1H), 5.09 (t, J = 9.7 Hz, 1H), 5.00 (d, J = 10.1 Hz, 1H), 4.78 (s, 1H), 
4.73 (q, J = 5.3 Hz, 1H), 4.68 (s, 1H), 4.60 (d, J = 11.5 Hz, 1H), 4.42 (d, J = 11.5 
Hz, 1H), 4.29 – 4.23 (m, 1H), 4.08 – 4.00 (m, 1H), 3.96 (d, J = 2.9 Hz, 1H), 
3.843 – 3.70 (m, 3H), 3.64 – 3.57 (m, 2H), 3.52 (s, 3H), 3.11 – 3.01 (m, 2H), 
2.74 – 2.61 (m, 3H), 2.56 (sept, J = 7.0 Hz, 1H), 2.52 – 2.39 (m, 2H), 1.97 – 
1.87 (m, 1H), 1.81 (s, 3H), 1.73 (s, 3H), 1.66 (d, J = 1.1 Hz, 3H), 1.32 (d, J = 6.1 
Hz, 3H), 1.30 – 1.23 (m, 1H), 1.22 – 1.11 (m, 15H), 1.09 (s, 3H), 0.83 (t, J = 7.4 
Hz, 3H) ppm; 13C NMR (126 MHz, acetone-d6) δ 176.8, 169.0, 167.8, 156.3, 
156.1, 147.0, 145.5, 143.5, 136.90, 136.86, 136.0, 133.8, 128.1, 126.3, 125.3, 
124.0, 111.7, 101.7, 96.8, 93.3, 82.6, 81.6, 78.2, 77.5, 75.7, 73.8, 72.8, 72.7, 
72.3, 70.6, 70.2, 67.7, 63.4, 61.7, 42.0, 37.3, 34.8, 33.9, 28.7, 28.4, 26.5, 20.7, 
19.4, 19.2, 18.6, 18.2, 17.5, 15.2, 14.8, 13.8, 11.2 ppm; HRMS ESI(+) (MeOH) 
calculated for C52H74ClIO18Na [M+Na]+: 1171.35006, found: 1171.35037. 
7: Rf = 0.23 (MeOH/CH2Cl2 1:18); Specific Rotation [𝛼𝛼]𝐷𝐷26 °𝐶𝐶  = −4.28 (c = 0.55, 
MeOH); FT-IR ?̃?𝜈 (film) 3433, 2977, 2934, 2876, 1732, 1697, 1644, 1453, 1385, 
1370, 1310, 1242, 1198, 1163, 1148, 1069, 1026, 901, 799, 713 cm−1; 1H NMR 
(500 MHz, acetone-d6) δ 7.24 (d, J = 11.5 Hz, 1H), 6.68 – 6.58 (m, 1H), 5.96 
(ddd, J = 14.6, 9.5, 4.6 Hz, 1H), 5.83 (s, 1H), 5.65 – 5.60 (m, 1H), 5.22 (dt, J = 
10.4, 1.6 Hz, 1H), 5.12 (t, J = 9.7 Hz, 1H), 5.00 (d, J = 10.1 Hz, 1H), 4.78 (d, J = 
1.2 Hz, 1H), 4.76 – 4.71 (m, 1H), 4.69 (s, 1H), 4.60 (d, J = 11.5 Hz, 1H), 4.42 
(d, J = 11.5 Hz, 1H), 4.30 – 4.23 (m, 1H), 4.03 (quint, J = 6.4 Hz, 1H), 3.96 (d, 
J = 2.9 Hz, 1H), 3.82 (dd, 1H), 3.77 – 3.68 (m, 2H), 3.67 – 3.54 (m, 2H), 3.52 
(s, 3H), 3.11 – 2.96 (m, 2H), 2.79 – 2.61 (m, 3H), 2.56 (sept, J = 78.2, 6.7 Hz, 
2H), 2.52 – 2.39 (m, 1H), 1.99 – 1.89 (m, 1H), 1.81 (d, J = 1.3 Hz, 3H), 1.73 (d, 
J = 1.4 Hz, 3H), 1.65 (d, J = 1.4 Hz, 3H), 1.30 (d, J = 6.1 Hz, 3H), 1.28 – 1.25 (m, 
1H), 1.25 (t, J = 7.5 Hz, 3H), 1.20 – 1.11 (m, 12H), 1.09 (s, 3H), 0.83 (t, J = 7.4 
Hz, 3H) ppm; 13C NMR (126 MHz, acetone-d6) δ 176.8, 169.7, 167.8, 160.1, 
157.6, 145.5, 144.9, 143.5, 136.9, 136.11, 136.08, 133.8, 128.1, 126.3, 125.2, 
124.0, 113.3, 109.1, 101.7, 96.8, 93.3, 81.6, 78.2, 77.8, 75.7, 73.9, 73.8, 72.9, 
72.8, 72.3, 70.6, 70.2, 67.7, 63.4, 61.7, 42.0, 37.3, 34.8, 28.7, 28.4, 26.6, 26.5, 
20.7, 19.4, 19.2, 18.6, 18.3, 17.5, 15.2, 14.3, 13.8, 11.1 ppm; HRMS ESI(+) 
(MeOH) calculated for C52H74ClIO18Na [M+Na]+: 1171.35006, found: 
1171.35027. 
4’’’-Iodo, 6’’’-Dechlorofidaxomicin (8) 
Pure dechlorinated compound 2 (8.6 mg, 8.7 µmol, 1.0 eq.) was dissolved in 
EtOH (180 µL) and cooled to 0 °C. Then, I2 (2.7 mg, 10.6 µmol, 1.2 eq.) was 
added in one portion and a solution of H5IO6 (1.2 mg, 5.3 µmol, 0.6 eq.) in 
H2O (10 µL) was added dropwise. The reaction mixture was allowed to stir 
at 0 °C for 1 h, was diluted with EtOAc (1 mL) and then quenched with 10% 
aq. Na2S2O3 (1 mL). The phases were separated, and the aqueous layer was 
extracted with EtOAc (3 x 2 mL). The combined organic layers were dried 
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over MgSO4, filtered and the solvent was evaporated under reduced 
pressure. The crude mixture was purified by preparative RP-HPLC (Gemini 
NX C18, 5 µ, 110 Å, 250 mm × 21.2 mm; solvent A: H2O + 0.1% HCOOH, 
solvent B: MeCN + 0.1% HCOOH; 20 mL/min; LC time program (min –% B): 
0.0 – 50%, 15.0 – 50%, 45.0 – 70%, 46.0 – 100%] to afford, after 
lyophilization, 8 (tR = 22.0 min, 1.3 mg, 1.2 µmol, 13%) as a colorless solid. 
Specific Rotation [𝛼𝛼]𝐷𝐷26 °𝐶𝐶 = −0.52 (c = 0.58, MeOH); FT-IR ?̃?𝜈 (film) 3441, 2977, 
2933, 2876, 1697, 1643, 1598, 1455, 1407, 1385, 1371, 1311, 1255, 1199, 
1163, 1147, 1116, 1069, 1029, 901, 846, 802, 772, 716, 629, 573, 530, 499, 
474, 464 cm−1; 1H NMR (500 MHz, acetone-d6) δ 7.23 (d, J = 11.4 Hz, 1H), 
6.69 – 6.56 (m, 1H), 6.51 (s, 1H), 5.96 (s, 1H), 5.88 – 5.78 (m, 1H), 5.63 (t, J = 
8.3 Hz, 1H), 5.22 (dt, J = 10.5, 1.5 Hz, 1H), 5.14 (t, J = 9.7 Hz, 1H), 5.00 (d, J = 
10.1 Hz, 1H), 4.78 (d, J = 1.4 Hz, 1H), 4.73 (q, J = 5.3 Hz, 1H), 4.69 (d, J = 0.9 
Hz, 1H), 4.60 (d, J = 11.4 Hz, 1H), 4.42 (d, J = 11.5 Hz, 1H), 4.29 – 4.25 (m, 
1H), 4.07 – 4.00 (m, 1H), 3.96 (s, 1H), 3.85 – 3.80 (m, 1H), 3.77 – 3.71 (m, 
2H), 3.63 (dd, J = 9.6, 6.2 Hz, 1H), 3.58 (d, J = 3.2 Hz, 1H), 3.52 (s, 3H), 2.92 – 
2.84 (m, 2H), 2.77 – 2.61 (m, 3H), 2.56 (sept, J = 6.8 Hz, 1H), 2.55 – 2.39 (m, 
2H), 1.99 – 1.90 (m, 1H), 1.81 (d, J = 1.4 Hz, 3H), 1.73 (d, J = 1.4 Hz, 3H), 1.66 
(s, 3H), 1.28 (d, J = 6.2 Hz, 3H), 1.24 (d, 1H), 1.21 (t, J = 7.4 Hz, 3H), 1.19 – 
1.12 (m, 12H), 1.09 (s, 3H), 0.83 (t, J = 7.4 Hz, 3H) ppm; 13C NMR (126 MHz, 
acetone-d6) δ 176.8, 171.5, 167.8, 164.5, 163.4, 150.3, 145.4, 143.4, 136.9, 
136.12, 136.09, 133.8, 128.2, 126.3, 125.3, 124.0, 110.3, 105.2, 101.8, 96.8, 
93.1, 81.8, 78.2, 77.3, 75.7, 73.8, 72.84, 72.80, 72.75, 72.3, 70.8, 70.1, 67.7, 
63.4, 61.7, 42.0, 37.3, 34.8, 30.0, 28.7, 28.4, 26.5, 20.7, 19.4, 19.2, 18.6, 18.3, 
17.5, 16.5, 15.2, 13.8, 11.2 ppm; HRMS ESI(+) (MeOH) calculated for 
C52H75IO18Na [M+Na]+: 1137.38903, found: 1137.38932. 
General Procedure for the determination of MIC values for S. aureus 
The strain Staphylococcus aureus ATCC 29213 was grown overnight at 37 °C 
on MH II agar plates. (BD™ BBL™ Mueller Hinton II Agar, BD Diagnostics). 
MIC values were determined by broth dilution method according to the 
recommendations of the Clinical and Laboratory Standards Institute (CSLI; 
U.S.A.). The inoculum size was about 7.5x105 colony forming units/well. The 
compounds were diluted in H2O from 1.0 mg/mL stock solutions in 50 % 
methanol/H2O in a 2-fold dilution series. The microtiter plates were 
incubated at 37 °C overnight. Afterwards, the MIC (lowest concentration of 
the compounds with no bacterial growth observed) was determined by 
visual inspection. 
General procedure for the determination of MIC values for M. tuberculosis 
MIC determination was essentially conducted as described recently.[57] 
Briefly, the Green-Fluorescent Protein (GFP) expressing recombinant 
Mycobacterium tuberculosis H37Rv rpsL[58] transformed with pOLYG-Pr-
GFP[59] was grown in Middlebrook 7H9-OADC with 0.05 % Tween 80 until 
mid-log phase (optical density at 600 nm OD600 = 0.3 – 1.0), diluted to an 
OD600 of 0.04 and 20 μl of the suspension were added to an equal volume 
of 12-point two-fold serial dilutions of the compounds in 7H9-OADC-Tween 
in 384-well plates in triplicates. Compound concentrations were in the range 
of 62.5 to 0.031 μM. Fluorescence was measured immediately after 
inoculation (background) and after 10 days of incubation at 37 °C. Dose 
response curves were fitted with a 4-parameter log-normal model. PMIN 
[-,-] and PMAX [-, 120] are the minimum and the maximum, respectively, 
PHill [0,-] indicates the steepness, and EC50 [-,-] the log-back transformed 
Minimal Effective Concentration 50. The computational and statistical 
analysis was conducted with R (3.0.1 – 3.1.1; https://www.r-project.org/). 
Dose response curves were fitted with the ´drc´ package. The inhibitory 
potency I was calculated with the equation I = 100-[100●(S-P)/N-P)]. S is the 
sample’s fluorescence while P and N derive from growth inhibition with the 
control drug (Kanamycin A) and solvent growth control measurements 
(DMSO 1.25 % vol./vol.), respectively. A fluorescence reduction of 90 % as 
compared to the no-drug control was reported as Minimal Inhibitory 
Concentration (MIC90). 
 
General procedure for the determination of MIC values for C. difficile 
MIC determination was carried out by Micromyx, LLC, 4717 Campus Drive, 
Kalamazoo, MI, USA 49008. 
Approximately 5 mg of each of the test compounds were provided. These 
were stored at -20°C until testing. On the day of the assay, the test articles 
were dissolved in 100% DMSO (dimethyl sulfoxide, Sigma; St. Louis, MO, Cat. 
No. 472301-500ML, Lot No. SHBH5551V) to a stock concentration of 3232 
μg/mL. The concentration range tested for these test agents was 16 – 0.015 
μg/mL. The comparator agents, metronidazole and clindamycin were 
































32 – 0.03  
Test Organisms  
Test organisms consisted of reference strains from the American Type 
Culture Collection (ATCC; Manassas, VA) and clinical isolates from the 
Micromyx repository (MMX; Kalamazoo, MI). Organisms were initially 
received at Micromyx and were streaked for isolation. Colonies were picked 
by sterile swab from the medium and suspended in the appropriate broth 
containing cryoprotectant. The suspensions were aliquoted into cryogenic 
vials and maintained at -80ºC.  
Prior to testing, all isolates were streaked onto Brucella Agar supplemented 
with hemin, Vitamin K and 5% sheep blood (Becton Dickinson [BD]; Sparks, 
MD, Cat. No. 297716, Lot No. 8256909) and incubated anaerobically at 35-
37°C for 44 – 48 hours.  
Additionally, Bacteroides fragilis ATCC 25285 and Clostridium difficile ATCC 
700057 were tested for purposes of quality control. 
Test Medium  
The medium employed for anaerobic testing in the broth microdilution MIC 
assay was Brucella Broth (BD, Cat. No. 211088, Lot No. 7128995), 
supplemented with hemin (Sigma, Lot No. SLBP5720V), Vitamin K (Sigma, 
Lot No. MKCG2075) and 5% laked horse blood (LHB, Cleveland Scientific; 
Bath, OH, Lot No. 474990).  
Broth Microdilution Assay  
The MIC assay method followed the procedure described by the CLSI[60,61] 
and employed automated liquid handlers (Multidrop 384, Labsystems, 
Helsinki, Finland; Biomek 2000 and Biomek FX, Beckman Coulter, Fullerton 
CA) to conduct serial dilutions and liquid transfers. The wells in columns 2 
through 12 in a standard 96-well microdilution plate (Costar) were filled with 
150 μL of the appropriate diluent (DMSO for the test agents; dH2O for 
metronidazole and clindamycin). The drugs (300 μL at 101X the desired top 
concentration in the test plates) were dispensed into the appropriate well 
in column 1 of the mother plates. The Biomek 2000 was used to make serial 
2-fold dilutions through column 11 in the “mother plate”. The wells of 
column 12 contained no drug and were the organism growth control wells.  
The daughter plates for testing of all isolates were loaded with 190 μL per 
well of supplemented Brucella broth with 5% LHB using the Multidrop 384. 
The daughter plates were prepared on the Biomek FX instrument which 
transferred 2 μL of 101X drug solution from each well of a mother plate to 
the corresponding well of each daughter plate in a single step. The wells of 
the daughter plates ultimately contained 190 μL of medium, 2 μL of drug 
solution, and 10 μL of bacterial inoculum prepared in broth.  
A standardized inoculum of each organism was prepared per CLSI 
methods.[60,61] For all bacteria, suspensions were prepared in supplemented 
Brucella broth supplemented with hemin and Vitamin K to equal the 
turbidity of a 0.5 McFarland standard. These suspensions were further 
diluted 1:10 in supplemented Brucella broth with 5% LHB. The inoculum was 
dispensed into sterile reservoirs (Beckman Coulter) and transferred by hand 
in the Bactron Anaerobe chamber so that inoculation took place from low 
to high drug concentration. A 10 μL aliquot of inoculum was delivered into 
each well. Inoculated daughter plates were stacked and placed in an 
anaerobic box with GasPak sachets (BD; Lot No. 6309689), covered with a 
lid on the top plate, and incubated at 35 – 37°C.  
The microplates were viewed from the bottom using a plate viewer after 46 
hours. For each mother plate, an un-inoculated solubility control plate was 
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observed for evidence of drug precipitation. The MIC was read and recorded 




The NMR spectra are available in the Supporting Information.  
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